{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:07:52Z","timestamp":1774512472128,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This single-center, real-world study exploratorily compared early PSA kinetics between apalutamide plus androgen deprivation therapy (ADT) and triplet therapy (ADT, apalutamide, and docetaxel).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was designed as a single-center retrospective cohort study. A total of 36 patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) and adverse prognostic features between January 2022 and September 2024 were included. Adverse prognostic features were defined as a Gleason score \u22658 and\/or high-volume disease according to the CHAARTED criteria. Patients were stratified according to first-line treatment into a doublet group receiving apalutamide plus ADT (n = 17) and a triplet group receiving docetaxel plus apalutamide and ADT (n = 19). All patients received ADT induction for no more than 2 weeks prior to the initiation of apalutamide.<\/jats:p>\n                    <jats:p>The primary endpoints were the time from apalutamide initiation to the first achievement of PSA90 and PSA95, defined as a \u226590% and \u226595% decline in PSA from baseline, respectively. Secondary endpoints included time to PSA &amp;lt;0.2 ng\/mL, time to undetectable PSA (PSA &amp;lt;0.09 ng\/mL), PSA nadir level, and time to nadir, and PSA levels at predefined time points.<\/jats:p>\n                    <jats:p>Given baseline imbalances in tumor burden and Gleason score between the two groups, multivariable Cox proportional hazards models were applied for adjustment. Restricted sensitivity analyses were conducted to assess the robustness of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The triplet group had a higher proportion of patients with high-volume disease and higher overall Gleason scores, indicating a greater baseline disease risk.<\/jats:p>\n                    <jats:p>Time-to-event analyses showed that the median time to PSA90 was 0.9 months in the triplet group compared with 2.1 months in the doublet group. Similarly, the median time to PSA95 was 1.0 months in the triplet group versus 2.1 months in the doublet group. After adjustment for age, Gleason score, CHAARTED tumor volume, and baseline PSA (log10-transformed) in multivariable Cox regression models, the triplet regimen remained independently associated with a shorter time to achieving PSA90 and PSA95 (PSA90: adjusted hazard ratio [aHR] = 2.50, 95% CI 1.16\u20135.40; PSA95: aHR = 2.22, 95% CI 1.03\u20134.78).<\/jats:p>\n                    <jats:p>Regarding secondary endpoints, no statistically significant differences were observed between the two groups in time to PSA &amp;lt;0.2 ng\/mL, time to undetectable PSA (PSA &amp;lt;0.09 ng\/mL), PSA nadir level, or time to nadir. Likewise, no significant differences were detected in absolute PSA levels at 3, 6, and 12 months after treatment initiation. Restricted sensitivity analyses yielded results consistent in direction with the primary analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort characterized by high-risk features, although patients in the triplet group had a greater baseline disease burden, the addition of docetaxel was associated with a more rapid and deeper decline in PSA. However, PSA levels at subsequent predefined time points converged between the two groups.<\/jats:p>\n                    <jats:p>Given the limitations in sample size and follow-up completeness, the findings of this study should be considered exploratory. Whether the triplet regimen confers long-term benefits in hard clinical endpoints and which patient populations are most likely to benefit, requires validation in larger, well-designed prospective studies with standardized follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1787398","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:15Z","timestamp":1774506795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early characterization of PSA dynamics in patients with metastatic hormone-sensitive prostate cancer receiving apalutamide-based regimens"],"prefix":"10.3389","volume":"16","author":[{"given":"Peiyan","family":"Yu","sequence":"first","affiliation":[{"name":"Oncology Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[{"name":"Oncology Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonxin","family":"Hu","sequence":"additional","affiliation":[{"name":"Oncology Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[{"name":"Oncology Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: A review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030119","article-title":"Multicenter real-world study: 432 patients with apalutamide in metastatic hormone-sensitive prostate cancer","volume":"32","author":"Encarnaci\u00f3n Navarro","year":"2025","journal-title":"Curr Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pros.70040","article-title":"Prostate-specific antigen response at six months predicts progression in metastatic hormone-sensitive prostate cancer treated with apalutamide","volume":"85","author":"Mart\u00ednez Osorio","year":"2025","journal-title":"Prostate"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1186\/s12885-025-14294-7","article-title":"Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer","volume":"25","author":"Boegemann","year":"2025","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00929-6","article-title":"Survival outcomes of apalutamide as a starting treatment: Impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)","volume":"28","author":"Maughan","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00723","article-title":"Early treatment intensification in metastatic hormone-sensitive prostate cancer","volume":"41","author":"Wala","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.05.037","article-title":"Postprogression survival of patients with metastatic hormone-sensitive prostate cancer who received darolutamide or placebo in combination with docetaxel and androgen deprivation therapy: Post hoc analysis of the phase 3 ARASENS trial","volume":"88","author":"Grimm","year":"2025","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: Analyses of the randomized phase 3 ARASENS study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.03.001","article-title":"Association of deep and durable prostate-specific antigen responses with outcomes in metastatic hormone-sensitive prostate cancer: Insights from ARASENS and ARANOTE trials","author":"Wallis","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1599292","article-title":"Triplet systemic therapy for hormone-sensitive prostate cancer: A critical review with a multidisciplinary approach","volume":"19","author":"Zapatero","year":"2025","journal-title":"Oncol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.07.002","article-title":"Apalutamide in patients with high burden of metastatic hormone-sensitive prostate cancer: A subgroup analysis of TITAN","volume":"8","author":"Rodriguez-Vida","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.08.007","article-title":"Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: A single-center analysis","volume":"8","author":"Wenzel","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"527.e9","DOI":"10.1016\/j.urolonc.2025.05.006","article-title":"PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors","volume":"43","author":"Mart\u00ednez-Corral","year":"2025","journal-title":"Urol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.03.019","article-title":"Prostate-specific antigen response as a prognostic factor for overall survival in patients with prostate cancer treated with androgen receptor pathway inhibitors: A systematic review and meta-analysis","volume":"11","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.01.010","article-title":"Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer","volume":"87","author":"Azad","year":"2025","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04465-7","article-title":"Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: A retrospective, single-center real-world cohort study","volume":"57","author":"Usui","year":"2025","journal-title":"Int Urol Nephrol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:16Z","timestamp":1774506796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1787398"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1787398","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1787398"}}